Merck & Co., Inc. (MRK)
| Previous close | 83.15 |
| Open | 82.15 |
| Bid | 82.77 x 800 |
| Ask | 0.00 x 900 |
| Day's range | 81.80 - 83.24 |
| 52-week range | 65.25 - 92.64 |
| Volume | 6,614,914 |
| Avg. volume | 7,882,400 |
| Market cap | 209.75B |
| Beta (5Y monthly) | 0.47 |
| PE ratio (TTM) | 20.21 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 2.44 (2.94%) |
| Ex-dividend date | 14 Sep 2020 |
| 1y target est | N/A |
- Reuters
EU agency recommends AstraZeneca-Merck drug Lynparza for two cancers
Prostate cancer is the second-most common type of cancer in men worldwide, while ovarian cancer is the fifth most common cause of cancer death in Europe. The EMA recommendation follows positive regulatory updates for Lynparza, which AstraZeneca has developed with Merck & Co Inc as it faces competition from British rival GlaxoSmithKline on cancer drugs.
- Zacks
Seattle Genetics Up on Two New Oncology Deals With Merck
Seattle Genetics (SGEN) strikes a couple of deals with Merck to co-develop ladiratuzumab vedotin for breast cancer and other solid tumors. Also, Merck will market the company's Tukysa in some places.
- Zacks
Merck Buys Rights to Co-Develop Seattle Genetics ADC Drug
Merck (MRK) buys rights to co-develop/co-commercialize Seattle Genetics' ladiratuzumab vedotin. It acquires exclusive license to commercialize Tukysa for HER2-positive cancers in Asia, the Middle East and Latin America
